Vancouver, British Columbia -- (SBWIRE) -- 05/14/2012 -- A total of $2,558,096 of promissory notes and warrants offering has been raised by the Infectious disease treatment developer BioRelix Inc. of New Haven, Connecticut, according to the information received by Boyd Clark Resource Capital Solutions from regulatory document.

RNA targets called riboswitches found in bacteria and fungi are being used by the company in making treatments for infectious diseases. The molecular biologist of Yale University, Ronald Breaker, is the one who discover riboswitches in his lab and the developments are based on his scientific research. Also functional riboswitches of one type (the TPP riboswitch) have been discovered in plants and certain fungi. TPP riboswitches have also been predicted in archaea, but have not been experimentally tested.

In January, $500,000 was received by the company from the state’s quasi-public authority responsible for technology-based economic development, the Connecticut Innovations. The investment was part of a $4.244 million round of funding for the company. And the company took in $3.6 million last September of a planned $5.3 million equity offering.

In 2007, Boyd Clark Resource Capital Solutions reported that BioRelix closed at $25.8 million Series A Funding round with Stamford, Connecticut’s CHL Medical Partners leading the investment.